As an additional safeguard, special consideration is being given to those categories of medicines considered most essential to public health. The HSE and the Health Products Regulatory Authority (HPRA) are working with key stakeholders to further assess key risk areas and to focus contingency planning efforts on potentially vulnerable medicines. They are seeking additional assurances from suppliers, verifying contingency planning and, where necessary, identifying clinically appropriate alternatives. This will ensure, insofar as is possible, continuity of care for patients in Ireland. The continued engagement and cooperation of stakeholders is appreciated.